Bio-Based Fiber Efficiency Patents: Leaders & White Space 2026
- Filing activity peaked in 2020 at 17 records then dropped sharply and has stayed flat through the most recent full year, suggesting a short, concentrated filing burst rather than a sustained buildout.
- B32B layered products dominate the IPC mix at 17 of 19 records, with A61F implant-adjacent claims close behind at 15 — the technology reads as nonwoven composite engineering as much as fiber chemistry.
- Filing is spread thin across receiving offices with Europe at 5 and no single office above that, pointing to a field still being tested jurisdiction by jurisdiction rather than consolidated around one market.
What this landscape covers
Bio-based fiber efficiency enhancement, as tracked here, sits at the intersection of nonwoven composite engineering and biopolymer fiber chemistry. The search string pulls records combining bio-based, biobased or biopolymer fiber language with claims to spinning efficiency, yield improvement or process efficiency — a narrow technical intersection rather than a broad materials category. The dataset is small: 19 published records, each treated as its own family in the assignee ranking, so no single filer’s continuation strategy is inflating the count.
Publication lags filing by roughly 18 months in most jurisdictions, so the most recent year on the trend chart understates real filing activity. Read the 2020 peak and the subsequent decline as the shape of a field that had a concentrated filing window rather than one still accelerating.
Filing trend and technology composition
Nineteen published families, mapped by year and by IPC subclass, show where claim density is concentrated and where filing has already tapered off.
A short, sharp filing window
Filings were absent in 2017, rose to a peak of 17 in 2020, then fell back — the 2022 midpoint sits at just 2. That pattern is more consistent with a cluster of related filings around one innovation cycle than a technology still building momentum.
Nonwoven composites lead, medicinal and cleaning uses follow
B32B (layered products & laminates) appears in 17 of 19 records and A61F (implants & prostheses) in 15, with A61K (medicinal preparations) and D04H (nonwovens & felts) also well represented. A47L, C11D and A61Q appear less often, marking cleaning and cosmetic end-uses as secondary rather than core claim territory.
Shares are the percentage of the 19 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Bio-Based Fiber Efficiency Enhancement with Eureka
This page is one run against one query. Ask Eureka your own question about bio-based fiber efficiency enhancement and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records
Water-soluble nonwoven composite structure (EP4382083A2)
The filing describes a nonwoven composite article built from two nonwoven webs of differing fiber diameter, fused at their interface, where at least one fiber population is a water-soluble polyvinyl alcohol fiber. The construction pairs a coarser first layer with a finer second layer to control dissolution and structural behaviour of the composite.Filed by MONOSOL, LLC; abstract text drawn from the published family record.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20220388269A1 | Nonwoven water-soluble composite structure | 7 |
| 2 | WO2021067474A1 | Nonwoven water-soluble composite structure | 6 |
Citation counts here reflect influence within this searched corpus and skew toward older records; treat them as a signal of prior-art density, not of current commercial relevance.
Publication numbers are shown where the record carries one (2 of 2 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data tells a filing strategy
Three patterns stand out once the filing trend and IPC composition are read together: a short filing burst, a composite-engineering core, and a thin geographic spread.
A concentrated burst, not a buildout
Filing rose from zero in 2017 to 17 in 2020, then fell to 2 by the midpoint year 2022. That trajectory looks like a single wave of related filings around a specific innovation rather than a technology entering sustained growth.
Layered composite structure is the real claim territory
B32B (layered products & laminates) appears in nearly every record, ahead of A61F implant-adjacent claims. Fiber chemistry claims are frequently wrapped inside a layered-composite structure claim rather than standing alone.
No office has consolidated the filing
Europe leads with 5 records, with Australia, Canada, Germany, India and the United States each at 2. That spread suggests applicants are testing jurisdictions individually rather than committing to one primary market.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bio-based fiber efficiency enhancement, with the prior art for and against each one.
Assignees and where the field is still open
With only 19 families in total, no assignee has built a dense thicket — most of the activity sits with one filer active around the 2020 peak, alongside a long tail of single-filing entrants.
Monosol anchors the corpus
Monosol's water-soluble nonwoven composite work, including the EP4382083A2 family, sits at the center of the most-cited records in this dataset. Recent-year momentum shows no new filings in the latest tracked year, consistent with the broader post-2020 decline.
A long tail, not a thicket
Outside the lead filer, the remaining records are spread thinly with no second concentration visible in the evidence. That leaves room for a new entrant to establish a position without displacing an incumbent portfolio.
Medicinal-use claims overlap fiber structure claims
Eleven records combine bio-based fiber efficiency claims with A61K medicinal preparation language, indicating that some filers are protecting fiber constructions for drug-delivery or wound-care contexts rather than textile use alone.
| Assignee | Recent year | YoY |
|---|---|---|
| Monosol, LLC | 0 | — |
Where to take this research
The filing trend and claim composition point to specific next steps for anyone deciding where to position new work.
Check the composite-structure claims before drafting
With B32B claims present in 17 of 19 records, any new filing on fiber efficiency should map its claim language against existing layered-composite structure claims first, not just fiber-chemistry prior art.
Run a claim clearance searchWatch for the next filing wave
The 2020 peak followed by a decline to 2022 suggests this field moves in bursts tied to specific innovations. A new commercial development could trigger a second wave worth monitoring early.
Set up filing alertsExplore the medicinal and cleaning cross-use angle
Overlap with A61K and C11D subclasses suggests fiber efficiency claims are migrating into drug-delivery and detergent-compatible nonwoven applications — an angle worth a dedicated search.
Explore adjacent IPC classesCommon questions on this landscape
This dataset contains 19 published patent families matching the combination of bio-based, biobased or biopolymer fiber language with spinning efficiency, yield improvement or process efficiency claims, covering 2015 through the 2026 data cutoff. That is a small, tightly-scoped corpus rather than a broad materials category, so counts should be read as indicative of a specific technical intersection, not the whole bio-based fiber field. Filing peaked in 2020 at 17 records and has since declined sharply.
Monosol is the most visible filer in this corpus, with its water-soluble nonwoven composite work, including the EP4382083A2 and related US and WO filings, ranking among the most-cited records. Beyond that lead filer, the dataset shows a long tail of entities with limited overlapping filings, meaning no single assignee has built a dense claim thicket across the full technology space. That leaves room for new entrants to stake out adjacent claim territory.
The trend data shows zero filings in 2017, a rise to a peak of 17 in 2020, and a drop to just 2 by the 2022 midpoint, with the most recent years remaining flat. This shape typically indicates a concentrated filing burst tied to a specific innovation cycle rather than sustained market growth. Readers should also note that publication lags filing by roughly 18 months, so the most recent years in any trend chart will always look thinner than the true filing rate.
B32B layered products and laminates appear in 17 of the 19 records, making layered composite structure the dominant claim territory rather than fiber chemistry in isolation. A61F implant and prosthesis classifications appear in 15 records, and A61K medicinal preparations in 11, showing significant overlap into biomedical and wound-care applications. Cleaning-appliance and detergent classifications (A47L, C11D) and cosmetics (A61Q) appear less frequently, marking those as secondary rather than core use cases in this dataset.
The evidence points to under-claimed territory in fiber-diameter gradient control across multi-web composites, dissolution-rate tuning for water-soluble fibers, and detergent-compatible nonwoven blends, none of which show heavy overlap with the dominant B32B and A61F claim cluster. Spinning-yield process claims that stand independently of composite structure claims are also comparatively rare in this corpus. Any filing strategy targeting these branches should still run a clearance search against the Monosol-anchored composite claims first, since those remain the most cited records in the space.
Research Bio-Based Fiber Efficiency Enhancement in depth with Eureka
Go past this page: query the whole bio-based fiber efficiency enhancement corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.